[{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Provides an Update on Its Product Portfolio, Following the FDA Acceptance of New Drug Application for the Product mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 3 Data of mdc-IRM, First Product Based On MedinCell\u2019s Technology, Shows Significant Improvements in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Phase II\/III Clinical Trial Launched for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"NFL Biosciences"},{"orgOrder":0,"company":"MedinCell","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Provides Additional Information Regarding the New Drug Application for mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using Medincell\u2019s Technology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"MedinCell","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$41.8 million","upfrontCash":"Undisclosed","newsHeadline":"France : EIB and MedinCell Sign a New \u20ac40 Million Loan Agreement to Support Development of Innovative Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation Of the Phase 3 Study for The Second Long-Acting Injectable Antipsychotic Using Medin Cell\u2019s Technology (Program mdc-TJK)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK \/ Olanzapine Long-Acting Injectable (LAI)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"MedinCell"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
TEV-44749 (olanzapine) is a novel D2/5-HT2 receptor inhibitor which is under phase 3 clinical development for the treatment of patients with Schizophrenia.
mdc-TJK (olanzapine) is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic receptor.
TV-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia.
Uzedy, a risperidone subcutaneous Long-Acting Injectable (LAI) for the maintenance treatment of schizophrenia using MedinCell’s proprietary technology.
The Phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting Injectable (LAI) formulation of mdc-TJK (olanzapine) for the treatment of patients with schizophrenia.
mdc-IRM, (risperidone) extended-release injectable suspension for the treatment of patients with schizophrenia (Teva codename: TV-46000), is the most advanced investigational product based on MedinCell’s BEPO® technology.
Company launching Phase II/III clinical trial of NFL-101, most innovative natural drug candidate in an advanced clinical development phase, could be first-line solution providing real support for people looking to stop smoking and for the treatment of their addiction.
MedinCell’s partner, Teva Pharmaceuticals, announced results from the pivotal Phase 3 Risperidone Subcutaneous Extended-release (RISE) study comparing TV-46000 once monthly (q1m) and TV-46000 once every two months (q2m) with placebo (1:1:1) in patients with schizophrenia.